Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional...
Day: December 23, 2025
Glucose Health, Inc. Completes Preferred Stock Conversion at an 85% Premium Positioning Company for Rapid Growth
BENTONVILLE, Ark., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition...
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and...
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention...
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the...
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory DiseaseCAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics,...
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage...
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while...
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific LeadershipLehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah,...
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec....
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved...
Vireo Growth Inc. Enters California and Florida and Strengthens Delivery Platforms with Acquisition of Eaze Inc.
Transaction will expand Vireo’s operating footprint to 10 states with 166 dispensaries and approximately 800,000 sq. ft. of cultivation and...
Burning Rock Announces Results of 2025 Annual General Meeting
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a...
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume...
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and...
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial1Wegovy® pill is indicated to reduce excess...
RxSight, Inc. Announces Chief Financial Officer Transition
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality...
Apollomics Reports First Half 2025 Financial Results
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...